Immuneering Corp (IMRX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$3.64

+0.22 (+6.43%)

Market Cap: $230.32M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

64%(14/22)

Avg Surprise

+1.99%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.31

Range$-0.37 - $-0.27

7 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.32+3.0%

60d ago$-0.310.0%

30d ago$-0.310.0%

7d ago$-0.310.0%

Current$-0.31

Revenue Consensus

Range$0 - $0

7 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.29

Range$-0.47 - $-0.20

7 analysts

Revenue Consensus

Range$0 - $0

7 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.29	$-0.47 - $-0.20	-	-	7	-	-
Sep 30, 2026Sep 26EST	-	$-0.31	$-0.37 - $-0.27	-	-	7	1 2 30d	-
Jun 30, 2026Jun 26 Reported Aug 5, 2026Reported Aug 5	$-0.27	$-0.26	$-0.31 - $-0.24	-3.85%	Miss	7	2 2 30d	+32.5%
Mar 31, 2026Mar 26 Reported May 15, 2026Reported May 15	$-0.21	$-0.35	$-0.41 - $-0.31	+40.00%	Beat	5	3 0 30d	+50.0%
Dec 31, 2025Dec 25 Reported Mar 6, 2026Reported Mar 6	$-0.18	$-0.31	$-0.37 - $-0.23	+41.94%	Beat	6	No revisions (30d)	+83.2%
Sep 30, 2025Sep 25 Reported Nov 12, 2025Reported Nov 12	$-0.38	$-0.39	$-0.48 - $-0.29	+2.56%	Beat	6	2 2 30d	+22.4%
Jun 30, 2025Jun 25 Reported Aug 13, 2025Reported Aug 13	$-0.40	$-0.40	$-0.48 - $-0.30	+0.00%	Beat	5	1 0 30d	+14.9%
Mar 31, 2025Mar 25 Reported May 5, 2025Reported May 5	$-0.42	$-0.58	$-0.66 - $-0.51	+27.59%	Beat	2	1 0 30d	+14.3%
Dec 31, 2024Dec 24 Reported Mar 20, 2025Reported Mar 20	$-1.07	$-0.45	$-0.73 - $-0.23	-137.78%	Miss	4	No revisions (30d)	-105.8%
Sep 30, 2024Sep 24 Reported Nov 13, 2024Reported Nov 13	$-0.49	$-0.55	$-0.60 - $-0.49	+10.91%	Beat	7	No revisions (30d)	-14.0%
Jun 30, 2024Jun 24 Reported Aug 6, 2024Reported Aug 6	$-0.47	$-0.53	$-0.56 - $-0.47	+11.32%	Beat	6	No revisions (30d)	-9.3%
Mar 31, 2024Mar 24 Reported May 7, 2024Reported May 7	$-0.49	$-0.50	$-0.59 - $-0.22	+2.00%	Beat	7	No revisions (30d)	+3.9%
Dec 31, 2023Dec 23 Reported Mar 1, 2024Reported Mar 1	$-0.52	$-0.47	$-0.53 - $-0.37	-10.64%	Miss	9	1 0 30d	-4.0%
Sep 30, 2023Sep 23 Reported Nov 9, 2023Reported Nov 9	$-0.43	$-0.49	$-0.56 - $-0.44	+12.24%	Beat	8	No revisions (30d)	+12.2%
Jun 30, 2023Jun 23 Reported Aug 3, 2023Reported Aug 3	$-0.43	$-0.53	$-0.62 - $-0.48	+18.87%	Beat	8	No revisions (30d)	+2.3%
Mar 31, 2023Mar 23 Reported May 4, 2023Reported May 4	$-0.51	$-0.56	$-0.63 - $-0.52	+8.93%	Beat	8	No revisions (30d)	-4.1%
Dec 31, 2022Dec 22 Reported Mar 6, 2023Reported Mar 6	$-0.50	$-0.58	$-0.61 - $-0.54	+13.79%	Beat	7	No revisions (30d)	-19.0%
Sep 30, 2022Sep 22 Reported Nov 10, 2022Reported Nov 10	$-0.49	$-0.48	$-0.54 - $-0.41	-2.08%	Miss	6	No revisions (30d)	-4.3%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$-0.44	$-0.52	$-0.54 - $-0.50	+15.38%	Beat	7	No revisions (30d)	+72.7%
Mar 31, 2022Mar 22 Reported May 10, 2022Reported May 10	$-0.49	$-0.44	$-0.46 - $-0.43	-11.36%	Miss	6	No revisions (30d)	+61.1%
Dec 31, 2021Dec 21 Reported Mar 10, 2022Reported Mar 10	$-0.42	$-0.39	$-0.47 - $-0.32	-7.69%	Miss	5	No revisions (30d)	+66.6%
Sep 30, 2021Sep 21 Reported Nov 9, 2021Reported Nov 9	$-0.47	$-0.62	$-0.73 - $-0.46	+24.19%	Beat	4	No revisions (30d)	+27.3%
Jun 30, 2021Jun 21 Reported Jul 30, 2021Reported Jul 30	$-1.61	$-1.44	$-1.94 - $-0.79	-11.81%	Miss	3	1 0 30d	-
Mar 31, 2021Mar 21 Reported Jun 2, 2021Reported Jun 2	$-1.26	$-1.25	-	-0.80%	Miss	-	-	-
Dec 31, 2020Dec 20 Reported Mar 31, 2021Reported Mar 31	$-1.26	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2019Dec 19 Reported Mar 30, 2020Reported Mar 30	$-0.65	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-3.50	EV/EBITDA	N/A
Price/FCF	-4.13x	FCF Yield	-24.20%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-52.10%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	19.47x	Quick Ratio	19.47x
Trading Statistics
Beta	0.46	Avg Volume	727.48K
52-Week High	$8.48	52-Week Low	$3.41

Technical Indicators Dashboard

Moving Averages

SMA 10$3.80

SMA 20$4.04

SMA 50$4.54

SMA 200$4.92

EMA 10$3.78

EMA 20$3.99

EMA 50$4.33

EMA 200$4.74

MACD

Line: -0.26Signal: -0.23Hist: -0.03

ADX

ADX: 33.3+DI: 13.6-DI: 33.6

Aroon & PSAR

Aroon UpN/A

Aroon Down100.0

PSAR$3.87

Bollinger Bands

Upper Band$4.68

Lower Band$3.40

%B Position3166%(Upper)

Band Width0.18

RSI (14-Day)

Neutral

35.3

Momentum Oscillators

Stoch %K10.9

Stoch %D13.2

Williams %R-70.1

ROC (10d)-9.7%

Momentum-0.39

CCI (20d)-125.8

MFI (14d)31.7

Volatility Measures

ATR (14d)$0.21(5.8%)

StdDev (20d)0.32

Hist Vol54.6%(High)

Volume Flow

VWAP$3.58

OBV1.4M

AD Line-28.7M

CMF (20d)-0.141

Volume Metrics

Avg Vol (20d)726.4K

Vol Ratio1.3x

VWMA (20d)$4.00

Pivot Points

R3$3.73

R2$3.66

R1$3.54

Pivot Point$3.48

S1$3.35

S2$3.29

S3$3.17

Advanced Oscillators

TSI-36.12

Ultimate Osc45.9

KST-186.05

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$726,326	$0	$0	$0	$-94,419,000	$0
Cost of Revenue	$0	$0	$612,729	$0	$0	$0	$174,645	$0	$0	$0	$185,216	$0
Gross Profit	$0	$0	$-612,729	$0	$0	$0	$-174,645	$0	$0	$0	$-185,216	$0

Operating Expenses	$19.00M	$15.34M	$13.75M	$15.38M	$14.76M	$15.48M	$18.56M	$15.27M	$14.91M	$15.33M	$16.30M	$13.93M
R&D	$14.00M	$10.65M	$9.25M	$10.87M	$10.45M	$11.47M	$14.86M	$11.25M	$10.65M	$11.20M	$11.91M	$10.05M
SG&A	$5.00M	$4.68M	$4.49M	$4.51M	$4.30M	$4.01M	$3.69M	$4.01M	$4.25M	$4.12M	$4.38M	$3.87M
Operating Income	$-19,000,408	$-15,335,034	$-13,752,717	$-15,380,706	$-14,757,894	$-15,484,652	$-18,558,155	$-15,273,748	$-14,913,748	$-15,325,750	$-16,301,987	$-13,926,338

Interest Income	$1.08M	$1.36M	$1.86M	$415,831	$324,013	$438,520	$415,240	$547,072	$826,104	$804,884	$754,143	$855,532
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$115,774	$0
Income Before Tax	$-17,270,427	$-13,974,630	$-11,891,675	$-14,964,875	$-14,433,881	$-15,046,132	$-18,279,942	$-14,597,366	$-14,079,927	$-14,520,866	$-16,417,761	$-12,595,211
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-17,270,427	$-13,460,895	$-11,580,010	$-14,964,875	$-14,433,881	$-15,046,132	$-18,051,486	$-14,597,366	$-14,079,927	$-14,307,829	$-15,083,492	$-12,595,211

EBITDA	$-18,840,400	$-15,651,038	$-13,825,259	$-15,294,549	$-14,666,051	$-15,392,074	$-18,520,412	$-15,082,312	$-14,815,894	$-15,389,863	$-16,196,492	$-13,677,116
EBIT	$-18,353,211	$-15,335,034	$-13,752,717	$-15,380,706	$-14,757,894	$-15,484,652	$-18,558,155	$-15,144,438	$-14,906,031	$-15,325,750	$-16,301,987	$-13,450,743

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about IMRX

News

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

This article highlights three companies that received new "Buy" ratings from Wall Street analysts. Lyell Immunopharma Inc., Immuneering Corp., and Atrium Therapeutics Inc. were initiated with bullish coverage...

Sahm•Aug 7, 2026 12:39 AM ET8/7/26•Neutral

BlackRock, Inc. (NYSE: BLK) discloses 6.7% ownership in Immuneering Corp (IMRX)

BlackRock, Inc. has disclosed a 6.7% ownership stake in Immuneering Corp (IMRX), as reported in a Schedule 13G SEC filing. This position amounts to 4,356,235 shares of Immuneering’s Class A stock as of June 30...

Stock Titan•Jul 28, 2026 4:41 PM ET7/28/26•Neutral

IMRX Valuation and Fair Value

P/E: -3.5x
P/FCF: -4.1x
P/B: 1.2x

See GNG's fair value

IMRX Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -52.1%
FCF yield: -24.2%

IMRX Competitors

Company	Ticker
Utah Medical Products Inc	UTMD
High Tide Inc	HITI
Q32 Bio Inc	QTTB
Lineage Cell Therapeutics Inc	LCTX
Fate Therapeutics Inc	FATE
Electromed Inc	ELMD
TriSalus Life Sciences Inc.	TLSI
Zentalis Pharmaceuticals Llc	ZNTL

Sector: Healthcare

IMRX Analyst Ratings

Consensus: Buy
Analysts: 7
Strong Buy: 2
Buy: 5
Hold: 0
Sell: 0
Strong Sell: 0

IMRX Bull Case vs Bear Case

Bull case

100.0% of IMRX's analyst ratings are Buy or Strong Buy.

Bear case

IMRX's quarterly revenue changed -99.8% year over year.

IMRX Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: -2.3%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.31
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 1 up, 2 down

Frequently Asked Questions About IMRX

Does IMRX pay dividends?

Immuneering Corp (IMRX) does not currently pay a regular dividend.

What is IMRX's market cap?

Immuneering Corp (IMRX) has a market capitalization of $230.32M with a current stock price of $3.64.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In

Earnings

Performance (10Y)

Upcoming Estimates

Key Metrics

Technical Indicators Dashboard

Moving Averages

MACD

ADX

Aroon & PSAR

Bollinger Bands

RSI (14-Day)

Momentum Oscillators

Volatility Measures

Volume Flow

Volume Metrics

Pivot Points

Advanced Oscillators

Financial Data

Related GNG Research

News

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

BlackRock, Inc. (NYSE: BLK) discloses 6.7% ownership in Immuneering Corp (IMRX)

IMRX Valuation and Fair Value

IMRX Profitability: Margins, ROIC and FCF

IMRX Competitors

IMRX Analyst Ratings

IMRX Bull Case vs Bear Case

Bull case

Bear case

IMRX Earnings: Beat Rate and Next Report

Frequently Asked Questions About IMRX

Related stocks

Get full access to GNG Research